Cancer Clinical Trials

Site: Liver, Pancreas and Biliary

The most recent listing of current clinical trials for liver, pancreas and biliary tract cancers appears below. Should you be interested in learning more about any of these clinical trials, please use our Contact Us form.

Site: Liver, Pancreas and Biliary
(Includes Liver, Pancreas
and Biliary Tract)

Protocol ID		Title

GV-001.004		A Randomized, Phase II Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. Keywords: first line treatment of unresectable locally advanced pancreatic cancer

Industry-pancreatic		A Phase II Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combine with a Gemcitabine Regimen v. a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations Keywords: post-resection RD/R1 pancreatic cancer with Ras mutations

National/Multicenter		TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients with liver Metastases from Primary Colorectal Cancer, Neuroendocrine Cancer or Non-Colorectal/Non-Neuroendocrine Cancer Keywords: liver Metastases from Primary Colorectal Cancer, Neuroendocrine Cancer or Non-Colorectal/Non-Neuroendocrine Cancer

BMS CA182-006		A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally at a Dose of 800mg, Daily or Doxorubicin Administered Intravenously at a Dose of 60mg/ M² Every 3 Weeks in Patients with Unresectable, Locally Advanced or Metastatic Hepaocellular Carcinoma Keywords: Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma

RP101		A Randomized, Double-Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma Keywords: Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma